Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Hepatic Impairment

Interventions

DRUG

otamixaban XRP0673

"Pharmaceutical form: solution for injection~Route of administration: intravenous"

Trial Locations (3)

Investigational Site Number 840001, Orlando

Investigational Site Number 840003, Miami Gardens

Investigational Site Number 840002, Knoxville